Patents by Inventor Beatriz M. Carreno
Beatriz M. Carreno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8088905Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: March 16, 2009Date of Patent: January 3, 2012Assignees: Wyeth, MedImmune LimitedInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
-
Publication number: 20110033451Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).Type: ApplicationFiled: June 30, 2010Publication date: February 10, 2011Applicant: Wyeth LLCInventors: Beatriz M. Carreno, Mary Collins, Jill F. Wright, Neil M. Wolfman, Maya Arai, Kenneth Jacobs, Zhijian Lu, Yongjing Guo, Yongchang Qiu
-
Publication number: 20100322897Abstract: The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.Type: ApplicationFiled: April 26, 2010Publication date: December 23, 2010Inventors: Jay K. Kolls, Florencia Marine McAllister, Beatriz M. Carreno, Samuel J. Goldman
-
Patent number: 7704503Abstract: The invention is related to findings that IL-17F-mediated inflammation of airway passages may be mediated via signaling through IL-17R on the basolateral surface of human respiratory epithelial cells. Thus, the present invention provides isolated and purified IL-17F or IL-17R polynucleotides and polypeptides. The present invention also is directed to novel methods for screening test compounds capable of inhibiting, i.e., decreasing, limiting, blocking, or otherwise reducing, IL-17F bioactivity, and methods for diagnosing, prognosing, and monitoring the progress of, disorders related to IL-17F bioactivity, e.g., disorders related to the effects of IL-17F binding to IL-17R on airway inflammation, e.g., in patients with cystic fibrosis, including pulmonary exacerbations due to bacterial infections in same. The present invention is further directed to novel therapeutics and therapeutic targets and to methods for the intervention (treatment) and prevention of said disorders related to IL-17F bioactivity.Type: GrantFiled: February 14, 2006Date of Patent: April 27, 2010Assignees: Wyeth LLC, University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Jay K. Kolls, Florencia Marine McAllister, Beatriz M. Carreno, Samuel J. Goldman
-
Publication number: 20100080809Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.Type: ApplicationFiled: August 28, 2009Publication date: April 1, 2010Applicants: Wyeth, The Government of the United StatesInventors: Mary Collins, Ethan Menahem Shevach, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young, Michael Chapman Byrne, Padmalatha S. Reddy, Geoffrey Laurence Stephens, Beatriz M. Carreno
-
Publication number: 20100028330Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: March 16, 2009Publication date: February 4, 2010Applicants: Medimmune Limited, WyethInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia-Valge Archer, John Andrews, Caroline Russell
-
Patent number: 7618632Abstract: The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.Type: GrantFiled: May 24, 2004Date of Patent: November 17, 2009Assignees: Wyeth, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Mary Collins, Ethan Menahem Shevach, Rebecca Suzanne McHugh, Matthew James Whitters, Deborah Ann Young, Michael Chapman Byrne, Padmalatha S. Reddy, Geoffrey Laurence Stephens, Beatriz M. Carreno
-
Publication number: 20090142806Abstract: The present invention provides isolated and purified polynucleotides and polypeptides related to the IL-17F signaling pathway. The invention also provides antibodies to IL-17F homodimers and IL-17A/IL-17F heterodimers, and methods of isolating and purifying members of the IL-17 family, including IL-17A/IL-17F heterodimers, from a natural source. The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating and/or preventing disorders related to IL-17F signaling, i.e., IL-17F-associated disorders, including, but not limited to, inflammatory disorders, such as autoimmune diseases (e.g., arthritis (including rheumatoid arthritis), psoriasis, systemic lupus erythematosus, and multiple sclerosis), respiratory diseases (e.g., COPD, cystic fibrosis, asthma, allergy), transplant rejection (including solid organ transplant rejection), and inflammatory bowel diseases or disorders (IBDs, e.g., ulcerative colitis, Crohn's disease).Type: ApplicationFiled: August 21, 2008Publication date: June 4, 2009Applicant: WYETHInventors: BEATRIZ M. CARRENO, MARY COLLINS, JILL F. WRIGHT, NEIL M. WOLFMAN, MAYA ARAI, KENNETH JACOBS, ZHIJIAN LU, YONGJING GUO, YONGCHANG QIU
-
Patent number: 7521051Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: December 22, 2003Date of Patent: April 21, 2009Assignees: MedImmune Limited, WyethInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
-
Patent number: 7488802Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: December 22, 2003Date of Patent: February 10, 2009Assignees: Wyeth, MedImmune LimitedInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Vila Valge-Archer, John Andrews, Caroline Russell
-
Publication number: 20080311117Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: August 17, 2007Publication date: December 18, 2008Inventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
-
Publication number: 20080241130Abstract: The invention provides a novel mouse IL-17F/IL-17A, and further provides uses of such mouse IL-17F/IL-17A in the characterization of the IL-17F/IL-17A heterodimer. The present invention is also related to polynucleotides and polypeptides of the IL-17F/IL-17A signaling pathway, and targeting of the IL-17F/IL-17A signaling pathway in methods of treating IL-17F/IL-17A-associated disorders. The invention thus provides methods of using isolated IL-17F/IL-17A heterodimer, e.g., in a mouse model of airway inflammation, and specific or selective IL-17F/IL-17A modulators (e.g., signaling agonists or signaling antagonists (e.g., specific or selective antagonistic antibodies, specific or selective antagonistic small molecules, etc.)). The invention also provides methods of screening for compounds capable of modulating IL-17F/IL-17A biological activity, e.g., IL-17F/IL-17A signaling antagonists (e.g.Type: ApplicationFiled: March 28, 2008Publication date: October 2, 2008Inventors: Jill F. Wright, Spencer C. Liang, Frances K. Bennett, Mary Collins, Beatriz M. Carreno
-
Patent number: 7034121Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.Type: GrantFiled: January 26, 2001Date of Patent: April 25, 2006Assignee: Genetics Institue, LLCInventors: Beatriz M. Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary S. Gray, Donna Morris, Denise O'Hara, Paul R. Hinton, Naoya Tsurushita
-
Patent number: 7029674Abstract: Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response.Type: GrantFiled: April 2, 2002Date of Patent: April 18, 2006Assignee: WyethInventors: Beatriz M. Carreno, John Leonard
-
Publication number: 20040213795Abstract: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: December 22, 2003Publication date: October 28, 2004Applicants: Wyeth, Cambridge Antibody TechnologyInventors: Mary Collins, Clive R. Wood, Beatriz M. Carreno, Deborah Luxenberg, Jason Jussif, Laura L. Carter, Frances K. Bennett, Viia Valge-Archer, John Andrews, Caroline Russell
-
Publication number: 20040053307Abstract: The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to upregulate the immune response serves as a therapeutic for an individual, e.g., who has a condition such as an immunosuppressive disorder or a tumor.Type: ApplicationFiled: June 17, 2003Publication date: March 18, 2004Applicant: WyethInventors: Clive R. Wood, Andrew J. Long, Beatriz M. Carreno
-
Publication number: 20020039581Abstract: The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.Type: ApplicationFiled: January 26, 2001Publication date: April 4, 2002Inventors: Beatriz M. Carreno, Clive Wood, Katherine Turner, Mary Collins, Gary S. Gray, Donna Morris, Denise O'Hara, Paul R. Hinton, Naoya Tsurushita